Chief Scientific Officer · Founder, Myricx Pharma
| Role | Organisation | Sources |
|---|---|---|
| Chief Scientific Officer · Founder | Myricx Pharma | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Prof Ed Tate. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Novartis is acquiring London biotech Myricx Bio for US$1.1 billion upfront plus milestone payments, handing Melbourne venture firm Brandon Capital a record return on the startup it seeded in 2019.
Also Forbes Australia
UK biotech Myricx Pharma launched with a £4.5 million seed round from Sofinnova Partners and Brandon Capital to advance its NMT-inhibitor cancer drug discovery work.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio